Hot Topics in Life Sciences Law Symposium
Mayer Brown and the Seton Hall Law School Center for Health & Pharmaceutical Law presented Hot Topics in Life Sciences Law, a symposium tailored to legal professionals and executives at the forefront of the biotech, pharmaceutical, and medical device industries.
The symposium explored emerging issues and legal trends impacting the life sciences industries, including:
- M&A trends and antitrust developments affecting dealmaking
- The Inflation Reduction Act: recent litigations and implications for innovation
- Technology and Pharma, from AI to Privacy: What are the key considerations for in-house counsel
- Lifecycle management for FDA-regulated products: navigating the intersection of FDA’s regulatory exclusivity regimes and patent protection
- Intellectual property developments shaping product lifecycles
Panelists:
Charlie Adams, Managing Director, Global Head of Life Science Tools and Diagnostics, Citi
William Coppola, Distinguished Practitioner in Residence at the Gibbons Institute of Law, Science & Technology, Seton Hall Law
Jeffrey Lee, VP and Head of IP, Sail Biomedicines
Sharick Naqi, Director and Senior Counsel IP Lead, Novartis Gene Therapies
David Opderbeck, Professor of Law and Co-Director of the Gibbons Institute of Law, Science & Technology, Seton Hall
Andrew J. Parker, Senior Vice President - Head of Global Business Development, bioMérieux Inc.
Kenneth Peist, VP, Intellectual Property, Dermavant Sciences, Inc.
Peter J. Pitts, President, Center for Medicine in the Public Interest, Visiting Professor, University of Paris School of Medicine
Brian Robinson, Head IP—Cardiovascular, Novartis
Brian Stone, Associate General Counsel, Global Legal-Regulatory, Viatris Inc.
Other Event Documents
- M&A trends and antitrust developments affecting dealmaking
- Healthcare M&A Update
- The Inflation Reduction Act: recent litigations and implications for innovation
- Technology and Pharma, from AI to Privacy: What are the key considerations for in-house counsel
- Intellectual property developments shaping product lifecycles
- Lifecycle management for FDA-regulated products: navigating the intersection of FDA’s regulatory exclusivity regimes and patent protection
- Artificial Intelligence in Pharmaceuticals, Biologics, and Medical Devices: Present and Future Regulatory Models
